Extent of disease activity assessed by 18F-FDG PET/CT in a Dutch sarcoidosis population

Sarcoidosis Vasculitis and Diffuse Lung Diseases

Volumn 31, Issue 1, 2014, Pages 37-45

  Cremers, J P ^a   Van Kroonenburgh, M J ^b   Mostard, R L ^c   Voo S A ^b   Wijnen, P A ^d   Koek, G H ^e   Drent, M ^a,f  

^a GELDERSE VALLEI HOSPITAL   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c Zuyderland Medical Centre   (Netherlands)

^d Dept of Clinical Chemistry MUMC+ ^*  (Netherlands)

^e Department of Internal Medicine   (Netherlands)

^f MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Extrathoracic; Inflammation; Positron emission tomography computed tomography (PET CT); Sarcoidosis

Indexed keywords

FLUORODEOXYGLUCOSE F 18; METHOTREXATE; PREDNISONE; RADIOPHARMACEUTICAL AGENT;

ABNORMAL LABORATORY RESULT; ADULT; AFRICAN AMERICAN; ARTHRALGIA; ARTICLE; ASIAN; BONE MARROW; CAUCASIAN; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DISEASE ACTIVITY; DYSPNEA; FATIGUE; FEMALE; FUNCTIONAL DISEASE; HUMAN; LUNG FUNCTION; LUNG FUNCTION TEST; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MYALGIA; PAROTID GLAND; PET-CT SCANNER; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SARCOIDOSIS; SPLEEN; COMPUTER ASSISTED TOMOGRAPHY; MIDDLE AGED; MULTIMODAL IMAGING; NETHERLANDS; POSITRON EMISSION TOMOGRAPHY; RADIOGRAPHY; SCINTISCANNING;

FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; MULTIMODAL IMAGING; NETHERLANDS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; SARCOIDOSIS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84900565560     PISSN: 11240490     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Hunninghake GW, Costabel U, Ando M, et al. ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and other Granulomatous Disorders. Sarcoidosis Vasc Diffuse Lung Dis 1999; 16 (2): 149-73.
2. Iannuzzi MC, Fontana JR. Sarcoidosis: clinical presentation, immunopathogenesis, and therapeutics. JAMA 2011; 305 (4): 391-9.
3. Baughman RP, Teirstein AS, Judson MA, et al. Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med 2001; 164 (10 Pt 1): 1885-9. (Pubitemid 33152325)
4. Baughman RP, Culver DA, Judson MA. A concise review of pulmonary sarcoidosis. Am J Respir Crit Care Med 2011; 183 (5): 573-81.
5. Reich JM. On the nature of sarcoidosis. Eur J Intern Med 2011; 23 (2): 105-9.
6. Bauer MP, Brouwer PA, Smit VT,Tamsma JT.The challenges of extrapulmonary presentations of sarcoidosis: A case report and review of diagnostic strategies. Eur J Intern Med 2007; 18 (2): 152-4. (Pubitemid 46330771)
7. Morgenthau AS, Iannuzzi MC. Recent advances in sarcoidosis. Chest 2011; 139 (1): 174-82.
8. Baughman RP, Drent M, Culver DA, et al. Endpoints for clinical trials of sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2012; 29 (2): 90-8.
9. Consensus conference: activity of sarcoidosis. Third WASOG meeting, Los Angeles, USA, September 8-11, 1993. Eur Respir J 1994; 7 (3): 624-7.
10. Judson MA, Baughman RP, Teirstein AS, Terrin ML, Yeager H, Jr. Defining organ involvement in sarcoidosis: the ACCESS proposed instrument. ACCESS ResearchGroup.A Case Control Etiologic Study of Sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 1999; 16 (1): 75-86. (Pubitemid 29164274)
11. Teirstein AS, Machac J, Almeida O, Lu P, Padilla ML, Iannuzzi MC. Results of 188 whole-body fluorodeoxyglucose positron emission tomography scans in 137 patients with sarcoidosis. Chest 2007; 132 (6): 1949-53.
12. 18F-FDG PET/CT in sarcoidosis management: review and report of 20 cases. Eur J Nucl Med Mol Imaging 2008; 35 (8): 1537-43.
13. Keijsers RG, Grutters JC,Thomeer M, et al. Imaging the inflammatory activity of sarcoidosis: sensitivity and inter observer agreement of (67)Ga imaging and (18)F-FDG PET. Q J Nucl Med Mol Imaging 2011; 55 (1): 66-71.
14. Keijsers RG, van den Heuvel DA, Grutters JC. Imaging the inflammatory activity of sarcoidosis. Eur Respir J 2012; 41 (3): 743-51.
15. Treglia G,Taralli S,Giordano A. Emerging role of whole-body 18F-fluorodeoxyglucose positron emission tomography as amarker of disease activity in patients with sarcoidosis: a systematic review. Sarcoidosis Vasc Diffuse Lung Dis 2011; 28 (2): 87-94.
16. 18F-FDGPET/CT for Diagnosis and Adjustment of Therapy in Patients with Active Chronic Sarcoidosis. J NuclMed 2012.
17. 18F-FDG PET, genotype-corrected ACE and sIL-2R in newly diagnosed sarcoidosis. Eur J Nucl Med Mol Imaging 2009; 36 (7): 1131-7.
18. Mostard RL, Voo S, van Kroonenburgh MJ, et al. Inflammatory activity assessment by F18 FDG-PET/CT in persistent symptomatic sarcoidosis. Respir Med 2011; 105 (12): 1917-24.
19. Mostard RL, Verschakelen JA, van Kroonenburgh MJ, et al. Severity of pulmonary involvement and (18)F-FDG PET activity in sarcoidosis. Respir Med 2013; 107 (3): 439-47.
20. Soussan M, Augier A, Brillet PY, Weinmann P, Valeyre D. Functional Imaging in Extrapulmonary Sarcoidosis: FDG-PET/CT and MR Features. Clin Nucl Med 2013 [Epud ahead of print].
21. Basu S, Saboury B,Werner T,Alavi A.Clinical utility of FDG-PET and PET/CT in non-malignant thoracic disorders.Mol Imaging Biol 2010; 13 (6): 1051-60.
22. Mostard RL, Prompers L, Weijers RE, et al. F-18 FDGPET/CT for detecting bone and bone marrow involvement in sarcoidosis patients. Clin Nucl Med 2012; 37 (1): 21-5.
23. De Vries J, Michielsen H, Van Heck GL, Drent M. Measuring fatigue in sarcoidosis: the Fatigue Assessment Scale (FAS). Br J Health Psychol 2004; 9 (Pt 3): 279-91. (Pubitemid 39277403)
24. Hoitsma E, De Vries J, Drent M. The small fiber neuropathy screening list: Construction and cross-validation in sarcoidosis. Respir Med 2011; 105 (1): 95-100.
25. Quanjer PH,Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung FunctionTests,European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl 1993; 16: 5-40.
26. Cremers J, Drent M, Driessen A, et al. Liver-test abnormalities in sarcoidosis. Eur J Gastroenterol Hepatol 2012; 24 (1): 17-24.
27. Mostard RL, Van Kuijk SM, Verschakelen JA, et al. A predictive tool for an effective use of (18)F-FDG PET in assessing activity of sarcoidosis. BMC Pulm Med 2012; 12: 57.
28. Mc Ardle BA, Leung E, Ohira H, et al. The role of F(18)- fluorodeoxyglucose positron emission tomography in guiding diagnosis and management in patients with known or suspected cardiac sarcoidosis. J Nucl Cardiol 2013; 20 (2): 297-306.
29. Baughman RP, Lower EE.Who dies from sarcoidosis and why? Am J Respir Crit Care Med 2011; 183 (11): 1446-7.
30. 18F-FDG PET in the diagnosis of cardiac sarcoidosis: a systematic review and meta analysis including the Ontario experience. J Nucl Med 2012; 53 (2): 241-8.